Total Annual Economic Burden of Patients with Sickle Cell Disease in Steady State in Greece

References

• DiPiro JT, Tolbert RL, Yee GC, et al. Pharmacotherapy: a pathophysiologic approach. 8th ed. Columbus (OH): McGraw-Hill Education; 2011.
   Google Scholar
• Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573.
   PubMed Web of Science ®Google Scholar
• Piel FB, Williams TN. Sickle cell anemia: history and epidemiology. In: Costa F, Conran N, Editors. Sickle Cell Anemia from Basic Science to Clinical Practice. Sao Paulo (Brazil): Springer International Publishing. 2016:23–47.
   Google Scholar
• Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484.
   PubMed Web of Science ®Google Scholar
• McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol. 2011;18(3):158–165.
   PubMed Web of Science ®Google Scholar
• Kalleas C, Anagnostopoulos K, Sinopoulou K, et al. Phenotype and genotype frequency of β-thalassemia and sickle cell disease carriers in Halkidiki, Northern Greece. Hemoglobin. 2012;36(1):64–72.
   PubMed Web of Science ®Google Scholar
• Adamidou D, Rouka E, Kyriakou D, et al. Severe sickle cell disease is characterized by low ADAMITS13/VWFQ: Ag ratio. Proceedings of the 54th American Society of Hematology Annual Meeting held at the Georgia World Congress Center, Atlanta, GA, USA on December 8-11 2012. Blood. 2012;120(21):3235.
   Google Scholar
• Voskaridou E, Ladis V, Kattamis A, et al. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol. 2012;91(9):1451–2458.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Kattamis A, Fragodimitri C, et al. National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality. Ann Hematol. 2019;98(1):55–66.
   PubMed Web of Science ®Google Scholar
• Sickle Cell Disease [Internet]. Boston (MA): Institute for Clinical and Economic Review (ICER). 2020 [accessed December 21 2020]. Available at: https://icer-review.org/material/sickle-cell-disease-draft-evidence-report/
   Google Scholar
• Cherry MG, Greenhalgh J, Osipenko L, et al. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. Health Technol Assess. 2012;16(43):1–129.
   Web of Science ®Google Scholar
• Delicou S, Diamantidis MD, Manganas K, et al. Sickle-cell disease in Greece: patient reported outcomes related to clinical complications, treatment choices and attitudes, beliefs and trends affecting potential participation in clinical trials – a Greek national multicentric study. Proceedings of the 61st American Society of Hematology Annual Meeting, held at Orlando, FL, USA on December 6-10 2019. Blood. 2019;134(Suppl 1):4838.
   Google Scholar
• Khoriaty AI. Sickle cell disease. A booklet for parents, patients and the community. In: Eleytheriou A, Angastiniotis M, Editors. Common Laboratory Tests. Nicosia (Cyprus): Thalassemia International Federation. 2008:35–42.
   Google Scholar
• Institute for the Study of Urological Diseases (IMOP). Categories of medical practices [Internet]. Thessaloniki (Greece): Institute for the Study of Urological Diseases. 2019 [accessed December 21 2019]. Available at: https://www.imop.gr/en
   Google Scholar
• Examination cost-healthgate4all.gr [Internet]. Athens (Greece); National & Kapodistrian University of Athens 2019 [accessed December 21 2019]. Available at: http://uoa.campaign.com.gr/pages/uoakiosk/en.php
   Google Scholar
• Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985–4991.
   PubMed Web of Science ®Google Scholar
• Osunkwo I, Andemariam B, Minniti CP, et al. Impact of sickle cell disease on patients’ daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY)). Am J Hematol. 2021;96(4):404–417.
   PubMed Web of Science ®Google Scholar
• Sickle Cell Society [Internet]. London (UK): Sickle Cell Society; 2019 [accessed December 21 2020]. Available at: https://www.sicklecellsociety.org/globalsurvey/
   Google Scholar
• Lesprit E, Lesprit P. [Infection in sickle cell disease]. Rev Prat. 2004;54(14):1574–1577. In French.
   PubMedGoogle Scholar
• Diagnosis related groups 2012-2017 [Internet]. Athens (Greece): Ministry of Health; 2018 [accessed December 21 2019]. Available at: https://www.moh.gov.gr
   Google Scholar
• Campbell A, Cong Z, Agodoa I, et al. The economic burden of end-organ damage among medicaid patients with sickle cell disease in the United States: a population-based longitudinal claims study. J Manag Care Spec Pharm. 2020;26(9):1121–1129.
   PubMed Web of Science ®Google Scholar
• Bulletin of revised prices of drugs for human use [Internet]. Athens (Greece): Ministry of Health; 2019 [accessed December 21 2019]. Available from: https://www.moh.gov.gr.
   Google Scholar
• Riley TR, Boss A, McClain D, et al. Review of medication therapy for the prevention of sickle cell crisis. P T. 2018;43(7):417–437.
   PubMedGoogle Scholar
• Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Am J Hematol. 2000;64(1):26–31.
   PubMed Web of Science ®Google Scholar
• Nietert PJ, Silverstein MD, Abboud MR. Sickle cell anaemia: epidemiology and cost of illness. Pharmacoeconomics. 2002;20(6):357–366.
   PubMed Web of Science ®Google Scholar
• Davis H, Moore RM, Jr, Gergen PJ. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep. 1997;112(1):40–43.
   PubMed Web of Science ®Google Scholar
• Huo J, Xiao X, Garg M, et al. The economic burden of sickle cell disease in the United States. [Abstract PSY10] Moving into action: informing policy and strengthening healthcare systems in Asia Pacific. Value in Health J. 2018;21(2):S108.
   Web of Science ®Google Scholar
• Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323–327.
   PubMed Web of Science ®Google Scholar
• Pizzo A, Laverty AA, Phekoo KJ, et al. A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11. J Public Health. 2015;37(3):529–539.
   Web of Science ®Google Scholar
• Anim MT, Osafo J, Yirdong F. Prevalence of psychological symptoms among adults with sickle cell disease in Korle-Bu Teaching Hospital, Ghana. BMC Psychol. 2016;4(1):53.
   PubMedGoogle Scholar
• Iolascon A, De Franceschi L, Muckenthaler M, et al. EHA Research roadmap on hemoglobinopathies and thalassemia: an update. Hemasphere. 2019;3(3):e208.
   PubMed Web of Science ®Google Scholar
• Lobitz S. Migration: the aftershocks to the provision of healthcare. 14th International Conference on Thalassaemias and Other Haemoglobinopathies and 16th Thalassaemia International Federation, held on November 17. Thal Rep. 2018;8(1):19.
   Google Scholar
• Taher AT, Musallam KM, Cappellini MD. βThalassemias. N Engl J Med. 2021;384(8):727–743.
   PubMed Web of Science ®Google Scholar